Biotech

Bioprocessing Summit 2026

Now in its 18th year, the Bioprocessing Summit unites a global community of scientists, engineers, and executives driving innovation and digitalization across process development, scale-up, quality, and analytics for biologics, antibodies, cell and gene, RNA, and oligonucleotide therapies. The event explores how technology, data, and AI are reshaping every s…

Visit the official siteRegister
57Speakers
101Sponsors
19On the bill · sessions
125Companies · in total
§I

Speakers

Programmed at Bioprocessing, in alphabetical order.
Andrea Arsiccio
Senior Scientist & Team Lead, In Silico · Coriolis Pharma Research GmbH
Anthony Blaszczyk
Senior Scientist, Global Biologics · USP
Anthony Mire-Sluis, PhD
Senior Vice President, Global Quality · Gilead Sciences
Ashna Dhingra
Bioprocess Technologies & Engineering, Senior Scientist · AstraZeneca
Can Araman
Senior Manager, Excipients R&D · Merck KGaA
Christian Bleiholder
Professor, Chemistry and Biochemistry · Florida State University
Christina S Alves
Head, US Biologics Process Development · Takeda
Christina S. Alves
PhD, Head, US Biologics Process Development · Takeda
Dan (Cassie) Liu
Principal Statistician · Bristol Myers Squibb
David Boggs
PhD, Senior Scientist · AbbVie
David Boggs, PhD
Senior Scientist · AbbVie
David Cho
Scientist I, ASO Process Development · Biogen
Delia Lyons
Principal Scientist, Process Sciences · AbbVie Inc.
Erik Bierwagen
Biosciences Portfolio Lead · Dassault Systemes
Glen R Bolton
PhD, Executive Director, Late Stage Bioprocess Development · Amgen Inc
Glen R. Bolton, PhD
Executive Director, Late Stage Bioprocess Development · Amgen, Inc.
Jacquelyn Blake-Hedges
Senior Scientist, Protein Biochemistry · Sutro Biopharma Inc
Jason Beckwith
PhD, DBA, Senior Vice President, Talent Science for Biopharma · Evolution
Jason P Beckwith
Senior Vice President, Talent Science for Biopharma · Evolution
Jennitte L Stevens, PhD
Chief Technical Operations Officer · insitro
Jerry Eriksson, MSc
Senior Research Scientist · AstraZeneca R&D
Jigesha Dholakia
Director, CMC Analytical Strategy, DA01 Analytical Workstream Lead · Bayer US LLC
§II

Sponsors

The houses behind the program. Tiers as disclosed.
ACROBiosystemsCorporate Support
Alpha Life SciencesCorporate Support
Alphalife SciencesCorporate Support
AnsysCorporate Support
ApohaCorporate Support
Argento ScientificCorporate Support
Astrea BioseparationsCorporate
ATUMCorporate
Beckman CoulterCorporate
Biologics Consulting GroupCorporate Support
Bionova ScientificCorporate
Bio RadCorporate
Bio-RadCorporate
BioviaCorporate
Boston BioproductsCorporate Support
CaladanCorporate Support
Caladan BioCorporate Support
Carr BiosystemsCorporate
CatalentCorporate
Catalent Pharma ServicesCorporate
Catalent Pharma SolutionsCorporate
ChemometecCorporate
ChimeCorporate Support Sponsor
Chime BiologicsCorporate Support
ChromaTanCorporate
CladeCorporate Support
c-LEctaCorporate Support
Cygnus TechnologiesCorporate
CytivaCorporate
Dassault SystèmesCorporate
Dassault SystemsCorporate
DemeetraCorporate
EcolabCorporate
Ecolab Life SciencesCorporate
FarrarCorporate Support
Fluid ImagingCorporate Support
Fluid Imaging / FlowCamCorporate Support
Fluid Imaging FlowCamCorporate Support
Fluid ImaginingCorporate Support
FormulatrixCorporate Support
§III

Agenda

Selected from 19 sessions on the bill.
  • TBA

    Accelerating Biologics Development with Predictive Stability Modeling

  • TBA

    Applied Automation and Mechanistic Modeling for Purification Development of Challenging Molecules under Accelerated Timelines

  • TBA

    Challenges and Strategies of 2’-NMA Chemistry in Oligonucleotide-Synthesis Process Development

  • TBA

    Characterizing Cellular Responses to Diverse Feeding Strategies in High-Intensity Dynamic Perfusion Bioprocesses

  • TBA

    Development of a Raman Model for Continuous Monitoring of Detergent Viral Inactivation

  • TBA

    Drug Product and Delivery of Cell Therapies

  • TBA

    Enhancing Control of Endotoxins during Oligonucleotide Purification

  • TBA

    Fully Automated and Closed Stem-Cell Expansion and Differentiation at a Commercial Scale

  • TBA

    Hydrophobic Interaction Chromatography (HIC) as an Innovative Platform for High Purity and Yield ASO Manufacturing

Intermission
Part the Second · For the Buyer

What does it mean when 125 companies show up — and 5 bet on three roles at once?

125 companies. five are betting more than once.

The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

Who's in the room
5All threespeak · spons · exh
90Sponsoringsponsor only
30Companies Speakingspeaker only

The Triple-Threat

CARR Biosystems·Cytiva·RedShift Bio·Revvity Signals·USP

Speakers by seniority

37% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.

  • C-suite47%
  • Founder / Owner24%
  • VP-level47%
  • Director / Head of1119%
  • Manager / Lead35%
  • Product12%
  • Engineer · IC24%
  • Research / Science2239%
  • Other roles814%

Of 57 on the bill · classified by free-text title

Most-represented companies
  1. 01AbbVie8V
  2. 02Biogen5V
  3. 03CARR BiosystemsSp·C2V
  4. 04AstraZeneca4V
  5. 05CytivaSp·C1V
  6. 06RedShift BioSp·C1V
  7. 07Revvity SignalsSp·C1V
  8. 08USPSp·C1V
  9. 09ACROBiosystemsSp·C
  10. 10Alphalife SciencesSp·C
  11. 11AnsysSp·C
  12. 12ApohaSp·C
  13. 13Argento ScientificSp·C
  14. 14Astrea BioseparationsSp·C
Sponsors by tier
corporate45
45% of 101
corporate sponsor2
2% of 101
corporate support50
50% of 101
corporate support sponsor2
2% of 101
premier2
2% of 101
Related events · by shared sponsors
  • AMP 2026November 11, 2026 · Seattle+ 2 shared